Accucaps’ over 500 employees, at its two facilities in Windsor and Strathroy, Ontario, join Catalent’s global network of 11 Softgel Technologies facilities. The Accucaps facilities house sizeable blistering, bottling, and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s.
London-based Quotient Clinical announced the deal Tuesday, saying it bought QS Pharma from Charles River to enlarge its “footprint in the U.S.” Quotient Clinical, which provides early-phase drug development, said it was particularly attracted to QS Pharma’s expertise in high potency, small molecule drugs. The manufacturing facility has an annual commercial capability of producing about 50 million units of solid oral meds and up to 10 million units for liquid products.
The company on Monday reported second quarter earnings of $483.7 million, up 10% in constant currency. It reported net earnings of $0.14 per diluted share, down 37% from the $0.24 per share from a year ago. Its adjusted net income of $0.27 a share beat analysts forecasts by a penny a share. Revenues outperformed the Street’s expectation by about $11 million.
Lonza said the cash deal with Capsugel owner KKR, which is expected to close in Q2 2017, includes refinancing $2 billion in Capsugel debt. Lonza said the acquisition should be acretive from the get-go and eventually provide about $100 million in savings through cross-selling opportunities and by combining manufacturing and services.
Catalent will add two Canadian manufacturing facilities to its softgel network through the acquisition of Accucaps.